Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jan 13, 2010

GVK Biosciences Joins ResearchPoint Global’s Worldwide CRO Network

  • India-based CRO GVK Biosciences has become part of ResearchPoint Global (RPG), a worldwide partnership comprising CROs and technology service providers.

    RPG claims GVK Bio will complement its existing presence in the Americas, Africa, as well as Western, Central, and Eastern Europe. It says that this expansion into India will offer a number of benefits for clinical trials, including a large population, qualified medical personnel, and well-established regulations.

    “This partnership enables GVK BIO to participate in global trials while focusing on local investigators/recruitment and leveraging lower local costs,” comments GVK Bio president, Manni Kantipudi. “While both ResearchPoint Global and GVK BIO are full-service CROs offering services independently, together, we hope to offer faster patient recruitment and access to our complete suite of functional services including clinical-data management, medical writing, and biostatistics.”


Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »